BLCO Q3 2025 Earnings Call Summary

Total Revenue: $1.281 billion, up 6% year-over-year (constant currency).
Adjusted EBITDA: $243 million, a 7% increase year-over-year; adjusted EBITDA margin of 19%.
Cash Flow: Adjusted cash flow from operations was $161 million, with adjusted free cash flow at $87 million.
Adjusted EPS: $0.18, excluding acquired IPR&D.
Segment Performance:
- Vision Care: Revenue of $736 million, up 6%, driven by strong performance in consumer and contact lenses.
- Surgical: Revenue of $215 million, up 1% (7% growth excluding enVista recall).
- Pharmaceuticals: Revenue of $330 million, up 7%, with Miebo generating $84 million (71% year-over-year growth).

Growth Drivers: Strong performance in pharmaceuticals, particularly Miebo and Xiidra, with Miebo showing 110% TRx growth year-over-year.
Product Pipeline: Upcoming innovations include new formulations in consumer products and a bioactive contact lens.
Operational Excellence: Introduction of a fourth strategic pillar, "financial excellence," focusing on cost management and efficient resource allocation.
Market Position: Continued growth in the contact lens market, with a 6% increase in overall contact lens portfolio revenue.

2025 Revenue Guidance: Maintained at $5.05 billion to $5.15 billion (5% to 7% constant currency growth).
Adjusted EBITDA Guidance: Updated to $870 million to $910 million, reflecting strong business performance.
CapEx: Expected to be approximately $295 million for the full year.
Tariff Impact: Management believes they can offset tariff impacts in 2025 but acknowledges the fluidity of the situation.

Gross Margin: Adjusted gross margin declined by 130 basis points year-over-year, primarily due to product mix and the enVista recall.
Market Conditions: Some softness in the contact lens market, particularly in Southeast Asia and China, with potential impacts from economic conditions affecting consumer confidence.
Competitive Pressures: The introduction of new competitors in the dry eye market, such as TRYPTYR, could impact Miebo's growth trajectory.

Financial Excellence: The new pillar focuses on ensuring efficient spending and resource allocation to drive growth and margin expansion.
Contact Lens Market: BLCO is outperforming the market, attributed to product innovation and effective execution. However, the overall market growth is expected to be at the lower end of mid-single digits.
Miebo's Profitability: While Miebo is performing well, its profitability timeline remains focused on 2026, with continued investments planned.
Generics Strategy: The U.S. generics business is viewed as opportunistic, focusing on maintaining profitability rather than aggressive growth.

This summary encapsulates the key aspects of the earnings call, highlighting both the successes and challenges faced by Bausch + Lomb in Q3 2025.

BLCO — Bausch + Lomb Corporation